To regulate blood sugar levels in those with diabetes, many people are prescribed a class of drugs known as SGLT2 inhibitors. SGLT2 inhibitors stop the kidney’s reabsorbing glucose, which in turn helps to lower blood sugar levels.

SGLT2 inhibitors are also used to help slow the progress of kidney disease in both diabetic and non-diabetic patients and have effectively increased the survival rate of those experiencing these conditions. What this means is that SGLT2 inhibitors are a vital treatment option for people with diabetic kidney disease or non-diabetic kidney disease.

Benefits of SGLT2 Inhibitors in kidney disease

What are SGLT2 Inhibitors?

SGLT2 inhibitors are a class of drugs that are most often used to treat the condition of type two diabetes. They assist the body in lowering blood sugar levels because they help it to process carbohydrates and sugars more effectively.

What are the Benefits of SGLT2 Inhibitors in kidney disease?

The better regulation of blood sugar is particularly beneficial to those with kidney disease because it means the kidneys do not have to work so hard. In turn, this means SGLT2 inhibitors are effective in reducing the progression of kidney disease, as well as type 2 as a treatment for type 2 diabetes.

Additionally, as well as being an effective treatment for those with type 2 diabetes and those with kidney disease, some SGLT2 Inhibitors such as Empagliflozin have been shown to reduce the risk of cardiovascular death or hospitalization for heart failure, with or without diabetes. Although, as good studies do, the research asks for additional work around this topic to strengthen the evidence.

Potential side effects of SGLT2 Inhibitors

Concerning the possible side effects of particular medications, those taking Dapagliflozin, or Empagliflozin, and need to be mindful of low blood sugar levels (hypoglycemia), genital yeast infections, and urinary tract infections. Some people may also experience weight loss, diarrhea, and nausea. In rare cases, this medication can lead to kidney failure, which is obviously a concern for those already experiencing kidney disease. Therefore. if you experience any of these side effects, please contact your healthcare provider.

Canagliflozin may also cause some serious side effects, including diabetic ketoacidosis (DKA) and diabetic foot ulcers. Some people taking canagliflozin have also developed kidney problems, especially those with diabetic kidney disease or non-diabetic kidney disease. Canagliflozin should be used with caution in these populations. In addition, canagliflozin may decrease survival in people with advanced diabetic kidney disease.

Common side effects of Ertugliflozin include urinary tract infections, vulvovaginal candidiasis, and increased urination. Other side effects include diabetic ketoacidosis, yeast infections, and kidney problems. Those taking the drug should be vigilant for symptoms of kidney damage. These include infrequent urination less often than normal, and edema (swelling) in your feet, legs, and ankles.

Ertugliflozin may also increase the risk of diabetic ketoacidosis in people with type 1 diabetes. Therefore, it is important to monitor blood sugar levels closely when taking this medication. People with diabetic ketoacidosis should seek medical attention immediately.

List of common SGLT2 Inhibitors medications including their trade and generic names